EGFR-Multiplex Set cfDNA in Plasma
The EGFR-Multiplex Set cfDNA in Plasma is a key resource for research and diagnostics, particularly for the detection of EGFR mutations associated with lung and breast cancers. EGFR mutations, which include both TKI-sensitive and resistant variants, are central to the progression of Non-Small Cell Lung Cancer (NSCLC). This product helps clinicians and researchers better understand and monitor these mutations, improving the accuracy of treatment selection and response tracking. The EGFR-Multiplex Set cfDNA in Plasma serves as a valuable positive control in liquid biopsy assays, offering high-quality cfDNA material derived from the Ashkenazim Son cell line and human-tech plasma. This material is essential for the validation and development of EGFR diagnostic kits, ensuring that assays are reliable and relevant for clinical and research applications. Incorporating this product into your laboratory or R&D department allows for enhanced diagnostic precision and supports the advancement of personalized medicine for NSCLC and other cancers driven by EGFR mutations. It is a crucial tool for detecting EGFR mutations, validating diagnostic assays, and improving therapeutic outcomes for patients with EGFR-driven cancers.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The EGFR-Multiplex Set cfDNA in Plasma is a key resource for research and diagnostics, particularly for the detection of EGFR mutations associated with lung and breast cancers. EGFR mutations, which include both TKI-sensitive and resistant variants, are central to the progression of Non-Small Cell Lung Cancer (NSCLC). This product helps clinicians and researchers better understand and monitor these mutations, improving the accuracy of treatment selection and response tracking.
The EGFR-Multiplex Set cfDNA in Plasma serves as a valuable positive control in liquid biopsy assays, offering high-quality cfDNA material derived from the Ashkenazim Son cell line and human-tech plasma. This material is essential for the validation and development of EGFR diagnostic kits, ensuring that assays are reliable and relevant for clinical and research applications.
Incorporating this product into your laboratory or R&D department allows for enhanced diagnostic precision and supports the advancement of personalized medicine for NSCLC and other cancers driven by EGFR mutations. It is a crucial tool for detecting EGFR mutations, validating diagnostic assays, and improving therapeutic outcomes for patients with EGFR-driven cancers.
- Comprehensive Mutation Coverage: Includes both TKI-sensitive and resistant EGFR mutations, essential for NSCLC therapy and research.
- Reliable Control Material: Serves as a high-quality positive control in liquid biopsy assays, ensuring accurate and consistent results.
- Ideal for Diagnostic Kit Validation: Supports the development and validation of EGFR diagnostic assays, advancing the quality of cancer diagnostics.
- Clinically Relevant cfDNA: Sourced from the Ashkenazim Son cell line and human-tech plasma, providing material that mirrors real-world clinical conditions.
The EGFR-Multiplex Set cfDNA in Plasma is a highly valuable reference material for research and diagnostics, particularly in the field of cancer detection. EGFR (Epidermal Growth Factor Receptor) mutations are well-known driver mutations, commonly found in cancers like lung and breast cancer. These mutations play a significant role in the development and progression of Non-Small Cell Lung Cancer (NSCLC), making the detection of EGFR mutations essential for effective therapeutic strategies.
The EGFR-Multiplex Set cfDNA in Plasma offers a selection of both TKI (tyrosine kinase inhibitor) sensitive and resistant mutations. This diverse range of mutations is crucial for understanding therapeutic responses and resistance mechanisms, ensuring more precise and personalized treatments for patients with NSCLC. By incorporating both TKI-sensitive and resistant mutations, the product enables comprehensive monitoring of EGFR-related therapy responses, contributing to better clinical outcomes.
This product is designed for use in diagnostic laboratories and research settings, where it can serve as a positive control in liquid biopsy assays. The EGFR-Multiplex Set cfDNA in Plasma is also ideal for the validation and development of EGFR diagnostic kits, supporting the ongoing evolution of more effective cancer diagnostic tools. The cfDNA used in this product is sourced from the Ashkenazim Son cell line and combined with human-tech plasma, ensuring high-quality, clinically relevant material for accurate testing and assay development.
Whether you are working in a laboratory setting or conducting cutting-edge research in the development of EGFR diagnostics, the EGFR-Multiplex Set cfDNA in Plasma provides the reliable and relevant material needed to drive accurate and effective results. With its use, researchers can advance the understanding of EGFR mutations, improve liquid biopsy assays, and enhance the diagnosis and treatment of NSCLC and other cancers driven by EGFR mutations.
EGFR-Multiplex Set cfDNA in Plasma
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
MSDS
This product as cfDNA in buffer can be found here:
Frequently paired with this kit
Other assays and instruments lab teams add alongside the EGFR-Multiplex Set cfDNA in Plasma.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
